


[> 2009](#)


[> 2008](#)


[> 2007](#)


[> 2006](#)


2009


- 
December 16, 2009


ExonHit announces the success of its capital increase
- 
December 3, 2009


ExonHit launches first product in Alzheimer
- 
November 5, 2009

ExonHit Therapeutics announces the appointment of its new Chief Financial Officer
- 
November 2, 2009

ExonHit will participate in the MAPT study for the prevention of cognitive decline in old people
- 
October 30, 2009

ExonHit presents new clinical advances on its Alzheimer's diagnostic and therapeutic programs
- 
October 26, 2009

ExonHit strengthens its intellectual property position in the US
- 
September 14, 2009

ExonHit presents promising first patient results for EHT 0202, its Alzheimer's candidate drug
- 
September 8, 2009

ExonHit will participate to the Paris Midcap Event on September 21 & 22



July 30, 2009

ExonHit Therapeutics First half 2009 results



July 8, 2009

ExonHit raises EUR 1.45 million through the exercise of warrants



June 26, 2009

ExonHit announces the departure of its Chief Financial Officer



June 16, 2009

ExonHit announces last patient out for EHT 0202 Phase IIa study in Alzheimer



May 27, 2009

ExonHit and Institut Gustave Roussy announce the signing of a license agreement for novel breast cancer diagnostic assay.



May 19, 2009

ExonHit enters into a liquidity agreement.



May 6, 2009

ExonHit's 2009 Extraordinary Annual Meeting.



April 28, 2009

ExonHit's 2009 Ordinary Annual Meeting.



April 16, 2009

ExonHit will participate to the paris Smallcap event.



March 31, 2009

ExonHit expands neurological research activities to epilepsy.



March 16, 2009

ExonHit reports proof of concept in breast cancer diagnostic using its SpliceArray™ platform.



March 9, 2009

ExonHit Therapeutics shareholders equity strengthened by exercise of more than half of its convertible bonds.



March 4, 2009

ExonHit Therapeutics invested strongly in 2008 for pivotal 2009 results.



February 26, 2009

ExonHit Therapeutics reports advancements in the clinical development of EHT 0202, its phase II drug for Alzheimer's disease.



January 6, 2009

ExonHit therapeutics expands strategic collaboration with allergan.

[Back to top](#)

2008



December 23, 2008

ExonHit Therapeutics allocates free subscription warrants to all shareholders.



December 3,2008

ExonHit is honoured by the innovation trophy from the national institute of industrial property.



November 27,2008

ExonHit launches mouse genome SpliceArray™ for use in human disease modeling studies.



October 29,2008

ExonHit announces new scientific publications on the use of SpliceArrayT.



September 22,2008

ExonHit exclusive partnership with Xentech to provide molecular profiling services.



July 29,2008

ExonHit Therapeutics achievements for first half.



July 2,2008

ExonHit presents therapeutic and diagnostic programs for Alzheimer at ICAD.



June 4,2008

Loic Maurel joins ExonHit therapeutics to become CEO.



May 6,2008

ExonHit therapeutics launches the rat genome SpliceArrayT products.



April 30, 2008

Appointment of Frederic Desdouits on the supervisory board of ExonHit Therapeutics.



March 31,2008

ExonHit appoints a new Management Board.



March 25,2008

Exonhits EHT 0202 counters scopolamines detrimental.



March 5,2008

ExonHit therapeutics financial results 2007.



January 16,2008

ExonHit builds a new organization.



January 9,2008

ExonHit and bioMerieux amend their strategic partnership.

[Back to top](#)

2007



January 4, 2007

ExonHit Therapeutics and bioMerieux initiate a third diagnostic programme



January 25, 2007

ExonHit raises 3.2 million euros through the exercise of warrants












February 20, 2007

ExonHit launches Human Genome SpliceArray™



February 26, 2007

ExonHit issues 400 000 new shares through the use of PACEO

- 
March 6, 2007
ExonHit 2006 financial results
- 
March 15, 2007
ExonHit identifies a panel of genes to diagnose, from a blood, Alzheimer's disease
- 
April 17, 2007
ExonHit Therapeutics and bioMérieux present additional results in their breast cancer blood biomarkers program
- 
May 11, 2007
Deborah Smeltzer appointed member of the supervisory board of ExonHit Therapeutics
- 
June 1st, 2007
ExonHit issues 400 000 new shares through the use of PACEO
- 
June 7, 2007
In 2009 ExonHit aims to ask for market clearance in Europe for a blood diagnostic test for Alzheimer's disease
- 
July 31, 2007
ExonHit Therapeutics - Achievements for first half 2007
- 
August 28, 2007
ExonHit strikes a milestone in its collaboration with Allergan
- 
November 8, 2007

ExonHit completes a prototype to detect Alzheimer's disease from blood



December 20, 2007

ExonHit initiates a Phase 2 clinical trial for EHT 0202 in Alzheimer's disease

[Back to top](#)

2006



November 23, 2006

ExonHit Therapeutics - Clinical Therapeutic Programs



November 8, 2006

Appointment of a new member of the Supervisory Board



October 25, 2006

ExonHit success of the issuance of convertible bonds



October 24, 2006

ExonHit presents preliminary characteristics of the issuance of convertible bonds



October 19, 2006

ExonHit to start a research program on a blood diagnostic for Atherosclerosis



September 20, 2006

ExonHit Therapeutics - solid first half 2006



September 19, 2006

ExonHit extends strategic alliance with Allergan



September 12, 2006

ExonHit appoints John Jaskowiak as Executive Business and marketing



September 12, 2006

ExonHit - internet portal to market its microarrays



September 7, 2006

ExonHit licences Merck rights to RNA splicing microarray patent



September, 7 2006

ExonHit produces a new map for human genome expression



July 25, 2006

First half 2006 revenues up by 46%



july 5, 2006

ExonHit - Financial press release calendar



June 7, 2006

ExonHit - Emission of free warrants












June 16, 2006

ExonHit - Success of the secondary offering



June 14, 2006

Changes in the secondary offering

- 
June 7, 2006
ExonHit - Secondary offering and free allocation of BSA
- 
May 31, 2006
Agilent and ExonHit expand agreement
- 
May 16, 2006
Alzheimer disease diagnostic patent
- 
April 18, 2006
SpliceArrays on Affymetrix GeneChip platform
- 
April 5, 2006
ExonHit announces the partial release of the lock-up for its principal shareholders
- 
March 29, 2006
ExonHit bioMÃ©rieux breast cancer
- 
February 21, 2006
2005 Financial Results
- 
February 17, 2006
ExonHit therapeutics will begin continuous trading on Alternext on March 6, 2006
- 
February 9, 2006

ExonHitâ SpliceArray service welcomes its 50th commercial project



January 5, 2006

ExonHit therapeutics strengthens its balance sheet

[Back to top](#)